GlassScriptPhysician profile
Makram Gedeon
NPI 1205030160
$4,300.90
in general payments reported to CMS, 2019-2025
11 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2021: $1,487 · 2022: $22.82 · 2023: $246 · 2024: $531 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,464 · Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,464.11 |
| Food and Beverage | $1,012.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,514.75 | 2025 | Linx Reflux Management System |
| Intuitive Surgical, INC. | $1,479.55 | 2019-2025 | Da Vinci Surgical System |
| W. L. Gore & Associates, INC. | $296.30 | 2021 | |
| Ethicon US, LLC | $279.71 | 2019-2025 | Linx Reflux Management System |
| Davol INC. | $249.67 | 2024 | Phasix Mesh |
| Medtronic, INC. | $176.02 | 2023-2024 | Signia, Endo Gia Ultra |
| Kci USA, INC. | $113.18 | 2023 | Prevena |
| Coopersurgical, INC. | $95.18 | 2024 | Advincula Delineator Uterine Manipulator |
| Covidien LP | $37.51 | 2019 | |
| Novo Nordisk INC | $31.16 | 2025 | Wegovy |
| Boston Scientific Corporation | $27.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Makram Gedeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.